CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5) When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF H2FPEF Score for Predicting Future Heart Failure in Stable Outpatients With Cardiovascular Risk Factors Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure

Original Research2018 Apr;198:145-151.

JOURNAL:Am J Cardiol. Article Link

Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial

Velazquez EJ, Morrow DA, DeVore AD et al. Keywords: sacubitril; valsartan; enalapril; NT-proBNP; acute Heart Failure episode

FULL TEXT PDF